Abstracts tagged "Compliance"

Abstract Number: 1243 • 2013 ACR/ARHP Annual Meeting
Osteoporosis Medication Adherence: Reasons For Stopping and Not Starting
Amy H. Warriner¹, Ryan C. Outman², Allison Wyman³, Fred H. Hooven⁴, Jonathan D. Adachi⁵, Roland Chapurlat⁶, Juliet E. Compston⁷, Cyrus Cooper⁸, Jeffrey R. Curtis⁹, Adolfo Díez-Pérez¹⁰, Robert Lindsay¹¹, Lyn March¹², Jeri W. Nieves¹¹ and Kenneth G. Saag¹³, ¹Endocrinology, Diabetes, and Metabolism, The University of Alabama at Birmingham, Birmingham, AL, ²Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Center for Outcomes Research, Center for Outcomes Research, UMass Medical School, Worcester, MA, ⁴University of Massachusetts, Worcester, MA, ⁵McMaster University, Hamilton, ON, Canada, ⁶Service de Rhumatologie et Pathologie Osseuse, INSERM UMR 1033 and Université de Lyon, Hôpital Edouard Herriot, Lyon, France, ⁷University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, ⁸MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ⁹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Internal Medicine, Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Barcelona; and RETICEF, ISCIII Madrid; Spain, Barcelona, Spain, ¹¹Helen Hayes, West Haverstraw, NY, ¹²Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ¹³Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Medication adherence with prescription osteoporosis medications is poor, with approximately half remaining adherent in the first year of treatment. Moreover, approximately one-third who are…
Abstract Number: 1247 • 2013 ACR/ARHP Annual Meeting
Association Between Bisphosphonate Switching Behavior and Cost Outcomes In Postmenopausal United States Veterans
Joanne Lafleur¹, Scott L. DuVall², Jeffrey R. Curtis³, Robert A Adler⁴, Tina Willson⁵, Irene Agodoa⁶, Bradley Stolshek⁷ and Richard E. Nelson⁸, ¹University of Utah College of Pharmacy, Salt Lake City, UT, ²VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Internal Medicine, Hunter Holmes McGuire VA Medical Center, Richmond, VA, ⁵Pharmacotherapy, University of Utah, Salt Lake City, UT, ⁶Amgen Inc, Thousand Oaks, CA, ⁷Amgen, Inc., Thousand Oaks, CA, ⁸Division of Epidemiology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Many bisphosphonate-treated patients discontinue therapy within the first year. Some later restart the same or a different bisphosphonate. The implications of this on total…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.